Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.
TCW MetWest Low Duration Bond Fund I-Class gained 3.76% (net of fees) in the third quarter of 2024 to outpace the ICE BofA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback